CA-HAI-ROBOTICS
31.3.2023 04:27:24 CEST | Business Wire | Press release
Hai Robotics, a leading provider of intelligent automated warehousing solutions, has won the MHI Innovation Award for Best Innovation of an Existing Product for their A42T Autonomous Case-handling Robot (ACR). This prestigious award was announced at ProMat 2023, held in Chicago, on Wednesday, March 22nd.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230327005769/en/
The MHI Innovation Award recognizes Hai Robotics for their groundbreaking work in developing advanced equipment for automated storage and retrieval solutions (ASRS) and recognizes the company's commitment to advancing their customer’s success with innovative and cutting-edge technology.
The A42T ACR is the first goods-to-person equipment that extends upward allowing facilities to store items up to 10m (32+ feet) high, while remaining independent of any storage medium. It is highly intelligent, able to handle most totes or container sizes and types, even cardboard boxes, on standard industry shelving structures. Comparable systems often require unique and expensive custom precision structures with limited tote options to function, but the A42T ACR is a revolutionary robotic design, freeing facilities of the old rigid ASRS constructs. This robot provides maximum system flexibility typically seen with AMR or AGV technology while allowing facilities to obtain modern warehouse density with maximum use of vertical storage.
This award is a testament to Hai Robotics’ dedication to excellence and its ability to deliver intelligent automation solutions that help businesses increase efficiency, reduce costs, reduce storage footprint, and improve overall productivity.
"We are thrilled to have won the Innovation Award at ProMat 2023," said Brian Zheng, CEO of Hai Robotics USA. "This award is a recognition of our team's hard work, dedication, and commitment to driving innovation in the industry. We are proud to be at the forefront of intelligent warehouse automation and are committed to delivering advanced solutions that help our customers stay ahead of the game."
The ProMat 2023 event brought together many thousands of industry experts, professionals, and businesses from around the world to showcase the latest technologies, products, and solutions in the field of automation and material handling. The event is an excellent opportunity for attendees to explore new technologies. Visitors were able to witness the A42T ACR live where it demonstrated 32-foot-high tote picks from one of the tallest structures built at the event.
"We are honored to have received this prestigious award, and we thank MHI for hosting such an exceptional event," said Rebecca Lennartz, Director of Marketing for Hai Robotics USA. "We look forward to continuing to drive innovation in the industry and helping businesses achieve their automation goals."
About HAI Robotics
Hai Robotics is a leading global provider of intelligent automated storage and retrieval systems (ASRS). Their ASRS solutions provide modern storage density, reducing their customer’s storage footprints up to 75%, increasing workflow efficiency gains up to 4x, maximizing order pick accuracy to 99.9+%, and improving daily orders fulfilled rate over 170%.
Their Autonomous Case-handling Robots (ACR) are the key equipment in their systems. These robots maximize the use of vertical space, managing the storage of goods 32+ feet high. Their solutions are independent of any storage medium so the ASRS can be built using almost any standard racking structure, and the equipment manages most kinds and sizes of bins, trays, cardboard cartons, and a variety of containers and materials.
Hai Robotics provides intelligent ASRS solutions made for real world applications.
To know more about Hai Robotics and their A42T ACR, visit their website at https://www.hairobotics.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230327005769/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom